# Marinomed Biotech AG Company Presentation

September 2023



## Disclaimer

This presentation (the "Presentation") was prepared by Marinomed Biotech AG.

The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of this information or opinions contained herein. Neither Marinomed Biotech AG nor any officer or employee of Marinomed Biotech AG or any person connected with them accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this Presentation or its contents or otherwise arising in connection therewith. Marinomed Biotech AG undertakes no obligation to update or correct any information contained herein or to otherwise advise as to any future changes to it.

Certain statements contained in this document may be statements of future expectations and other forward looking statements that are based on management's current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements.

Certain figures in this presentation have been rounded in accordance with commercial principles and practice. Such figures that have been rounded in various tables may not necessarily add up to the exact total given in the respective table.

This Presentation does not constitute or contain any investment advice. It is not and shall not be construed as an offer, invitation, recommendation or solicitation to sell, issue, purchase or subscribe for any securities in any jurisdiction or to enter into any transaction.


By accessing this Presentation, you represent, warrant and undertake that you have read and agree to comply with and to be bound by the contents of this disclaimer.

Logos and images of medical products in this presentation are for illustration purposes only and do not constitute advertising. Note: Information on effects and possible undesirable side effects is provided by the directions for use, doctor or pharmacist.



# Marinomed at a glance

Publicly listed biopharmaceutical company located in Korneuburg, Austria




#### Prime Market Segment of the Vienna Stock Exchange

MARI:AV; ATMARINOMED6; MARI.VI Part of ATPX, AP8, AXGP, NAP8, TAP8, WBI partnerships for customers

## **Business Model**

Lean organization & existing business



# **Equity Story**

Solid existing business, growth perspective through late-stage pipeline assets

- Experienced management team
- Solid revenue from marketed product portfolio
- Three key assets in partnering:
  - Carragelose portfolio
  - Budesolv
  - Tacrosolv
- Lean and efficient business model: cost-efficient approach along entire value chain







## **Therapeutic Areas**

Proven track record with clinically validated and patent-protected technologies




#### $S_{0} = V^{40}$ Solubilization technology partnerships for customers based on Marinosolv


• Several successful feasibility studies & partners entering phase II

# Carragelose overview

#### Mode of action



Without Carragelose: Virus enters mucosal cell



With Carragelose: Barrier prevents internalization of virus In-vitro data against respiratory viruses (selection)

Rhinoviruses

Coronaviruses, including SARS-CoV2

Influenzaviruses A, B

Parainfluenza viruses

Respiratory syncytial virus (RSV)

Adenoviruses

#### **Benefits**

- Polymer extracted from red seaweed
- Forms non-specific layer that protects mucosa from viruses & pollen → multi-purpose
- Favorable safety profile
- Clinically validated
- Patent-protected

# carragelose geos


Marinomed Biotech AG

Moisturizing and protective layer against viruses and pollen – multi-use potential



## Marinosolv overview

#### Mode of action



#### **Benefits**

- Solubilization of poorly watersoluble compounds
- Significantly
  increases bioavailability
- **Dose reduction**: Reduces side effects
- Faster onset of action
- **Eco-friendly**: Reduces pharmaceutical compounds in wastewater
- Clinically validated
- Patent protected
- Suitable for **sensitive tissues** such as eyes and nose

# Solv4U overview

PHASE I	PHASE			PHASE III		PHASE IV	
FEASIBILITY		FORMULATION DEVELOPMENT		PRECLINICAL & CLINICAL STUDIES		TECH TRANSFER	
Enhanced solubility of target compound with Marinosolv®	Provide r	e formulation & non-GMP material for al studies		Target Product Profile (TPP) & study support		Enable manufacturing at Contract Manufacturing / Research Organization	
LICENSE MODEL Patients' benefits Manufacturers' benefits						acturers' benefits	
Milestones and royalties through		Faster onset of action		Easily scalable process			
clinical development phase and beyond		Dose reduction			Increased sustainability of manufacturing		

Lower possible side effects

administration

Well-tolerable local and systemic

Option for preservative free formulations

Aseptic filtering of formulation

## Pipeline

Late-stage projects with low risk and high upside potential

#### **Development pipeline**

Therapeutic area	<b>Product</b> Indication	Status	Preclinical	Phase I	Phase II	Phase III	Filing/ Certification
IMMUNOLOGY	Budesolv/MAM-1004-1 Allergic rhinitis	Filing in preparation					
	Tacrosolv/MAM-1003-1 Inflammatory eye diseases	Phase II clinical study					
	<b>MAM-1004-2</b> Autoimmune gastritis	Preclinical					
VIROLOGY	MAM-1001-3 eye drops Dry eyes	Pre-Launch					
	Carravin/MAM-2001-1 Nasal congestion	Filing in progress					
	Inhaleen/MAM-1001-1 Viral pneumonia	Phase I clinical study					

#### **Commercialized products**

VIROLOGY

**Carragelose product portfolio** Viral respiratory infections Portfolio of seven different products (nasal & throat sprays, lozenges), marketed in >40 countries

# Highlights year-to-date 2023

Progress and new developments





### Record H1 revenues


Carragelose strong in H1 with post-pandemic slow-down of customer orders

#### Development of half-yearly revenues (m€)



HI 2019 H2 2019 HI 2020 H2 2020 HI 2021 H2 2021 HI 2022 H2 2022 HI 2023

#### Development of half-yearly EBIT (m€)



HI 2019 H2 2019 HI 2020 H2 2020 HI 2021 H2 2021 HI 2022 H2 2022 HI 2023

#### Comments

#### Historical numbers

- Revenues rose from €4.9m to €5.2m (+7%)
- EBIT slightly decreased from €2.5m to €2.9m due to higher R&D expenses

#### Cautious but optimistic outlook

- Customers anticipating end of the pandemic
- Current H2 order volume for Carragelose products leads to decline of revenue from sale of products
- Optimistic in the medium term, as many initiatives are underway:
  - Business development processes for the two main Marinosolv-assets Budesolv and Tacrosolv
  - Approval in Mexico leading to preparation for launch, expected to result in revenue within 6 months
  - Launches for Carragelose eye product and allergy product in preparation (H1 2024)
  - Further partnering for Carragelose-assets in negotiation with revenue potential in 2024

## Cash visibility into 2024

© Marinomed Biotech AG

Carragelose revenues reducing cash burn, repayment of loans ongoing




- Operations mainly consisting of personnel costs and R&D expenses; MDR switch temporarily also contributing
- 2 Strong quarters in terms of Carragelose revenue contributing significantly to reducing cash burn
- 3 Repayment of EIB loan started increasing cash burn – next significant repayment in Oct 2024 of €4m plus accrued interest on Tranche 1

 Cash burn under control, repayment of EIB loan to be earned through licensing deal

14

# Marinomed strategic priorities

Focus on revenue generation with existing products and product candidates



- Long-term adherence to our mission
- Funding promising pipeline programs through own cash flows

- Expanding business with a focus on assets that are ready for partnering
- Fill white spots on partnering map
- Accelerating profitable growth of existing business
- Supporting partnerships towards revenue generation

# Carragelose – growth strategy

Expansion of territory, indication and product portfolio

Target	Action item	Status / next steps		
Territory expansion - registration	USA (Procter & Gamble), Mexico and Brazil (M8 <sup>1</sup> )	USA → FDA registration <b>Mexico → received market approval</b> Brazil → ANVISA registration		
<b>Territory expansion – partnering</b> Focus on Asia, Japan and whi		Continue business development and negotiate deals		
Expansion of indication	nsion of indication blocker – full year product			
Expansion of product portfolio	Carragelose <b>eye drops</b> Prepare <b>allergy blocker</b> launch <b>Inhalation</b> medical device	<b>Eye drop launch planned for 2024</b> Upgrade allergy blocker registration for MDR compliance; <b>launch 2024</b> certify product as medical device		

### Immunology – focus on business development Expansion of territory, indication and product portfolio

Area / Product	Action item	Status / next steps		
<b>Tacrosolv (MAM-1003-1)</b> Inflammatory eye diseases	Run a structured BD process with external support	Complete the BD process and enable a partnership within the next 6-12 months		
Budesolv (MAM-1004-1)	Continue ongoing BD efforts and discussions with potential partners	Enable a near term partnership		
Allergic rhinitis	Support Chinese partner Luoxin and enable progress in China	Preparation for IND <sup>1</sup> in China – complete production establishment		
<b>Solv4U</b> Marinosolv for external customers	Increase BD activities - continue working on ongoing projects	A series of feasibility projects have been completed - progress current projects to licensing partnerships <b>First long-term partnership with SF</b> <b>Sine in China</b>		



## Financial calendar & IR contact

#### Financial Calendar 2023

November 21, 2023 Publication of the Results Q1-3 2023



#### **Stephanie Kniep**

Investor Relations phone: +43 2262 90300 226 e-mail: IR@marinomed.com

